PP.22.17] COMPARISON OF DECREASE IN URINARY ALBUMIN EXCRETION ACCORDING TO FIMASARTAN DOSING OF EVENING VERSUS MORNING IN NEVER-TREATED HYPERTENSIVE PATIENTS

Abstract

Objective: Previous results indicated that some aldosterone receptor blockers (ARB) at evening administration, as opposed to upon morning, might improve the diurnal/nocturnal ratio of blood pressure and urinary albumin excretion (UAE). The bedtime dosing of fimasartan compared to morning dosing effects on blood pressure and UAE is still uncertain. Design and method: Data from a 12-week prospective, randomized, open-label, blinded endpoint trial on 97 previously never-treated hypertensive patients, who were assigned to receive fimasartan (60 mg/day) as a monotherapy either on morning or evening, were included. Blood pressure was measured every 15 min during the day and every 30 min during the night for 24 consecutive hours before and after 3 months of treatment. Urinary excretion was calculated to use the urine albumin/creatinine ratio of morning spot urine. Results: The significant blood pressure reduction after 3 months of fimasartan (P < 0.001) was similar for both treatment times (10.8 and 10.2 mmHg reduction in the 24-h mean of systolic and diastolic blood pressure with morning administration; 7.4 and 10.9 mmHg with evening administration). Urinary albumin excretion was significantly reduced by 49% after awakening treatment and by 21% after bedtime treatment. Conclusions: Fimasartan significantly reduced the blood pressure, and urinary albumin excretion, however, the expected difference of dosing regimen evening versus morning effect on urinary albumin excretion was not detected.